FGP
AUPH icon

Freestone Grove Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Freestone Grove Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$979K Sell
57,717
-30,272
-34% -$484K 0.01% 544
2026
Q1 		$1.3M Buy
87,989
+74,367
+546% +$1.09M 0.01% 428
2025
Q4 		$217K Buy
+13,622
New +$193K ﹤0.01% 692

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's AUPH Position: Q2 2026 in Review

Freestone Grove Partners reduced its Aurinia Pharmaceuticals (AUPH) stake by 34% in Q2 2026, selling an estimated $484K and leaving 57,717 shares worth $979K. The position accounts for 0.01% of the portfolio, ranked #544.

Freestone Grove Partners first reported a position in AUPH in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.3M in Q1 2026. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Freestone Grove Partners held 57,717 shares of Aurinia Pharmaceuticals worth $979K as of Q2 2026.
  • Freestone Grove Partners sold 30,272 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $484K.
  • Aurinia Pharmaceuticals made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #544 holding.
  • Freestone Grove Partners first reported a position in Aurinia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Freestone Grove Partners's Aurinia Pharmaceuticals position peaked at $1.3M in Q1 2026.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.